Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease-Reference-Cited by-同舟云学术

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Published:2009-05-19 Issue:19 Volume:119 Page:2545-2552
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Gutiérrez Orlando M.¹,Januzzi James L.¹,Isakova Tamara¹,Laliberte Karen¹,Smith Kelsey¹,Collerone Gina¹,Sarwar Ammar¹,Hoffmann Udo¹,Coglianese Erin¹,Christenson Robert¹,Wang Thomas J.¹,deFilippi Christopher¹,Wolf Myles¹

Affiliation:

1. From the Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Fla (O.M.G., K.S., M.W.); Cardiology (J.L.J., T.J.W.) and Nephrology (T.I., K.L., G.C.) Divisions, Department of Medicine, and Department of Radiology (A.S., U.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Cardiovascular Medicine Section, Department of Medicine, Boston University School of Medicine, Boston, Mass (E.C.); and Department of Pathology (R...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference46 articles.

1. Prevalence of Chronic Kidney Disease in the United States

2. Myocardial interstitial fibrosis in experimental uremia—Implications for cardiac compliance

3. Left Ventricular Hypertrophy in the Renal Patient

4. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease

Cited by 733 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Markers of Bone Mineral Disease and Left Ventricular Hypertrophy in Patients of Chronic Kidney Disease;Acta Medica Bulgarica;2024-09-01

2. Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis;npj Cardiovascular Health;2024-08-21

3. Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence;Clinical Kidney Journal;2024-07-18

4. The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?;Pharmacology & Therapeutics;2024-07

5. Cardiovascular health in pediatric patients with X-linked hypophosphatemia under two years of burosumab therapy;Frontiers in Endocrinology;2024-05-16